Elicio Therapeutics (ELTX) grants 52,832 stock options to Chief Scientific Officer
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Elicio Therapeutics, Inc. reported that Chief Scientific Officer Peter DeMuth received a grant of stock options covering 52,832 shares of common stock. The options have an exercise price of 3.2000 per share and expire on 2036-07-16. They vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, leaving him with 52,832 options outstanding after this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
DeMuth Peter
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 52,832 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 52,832 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 52,832 shares
Exercise price: 3.2000 per share
Options after grant: 52,832 options
+3 more
6 metrics
Options granted
52,832 shares
Stock Option (Right to Buy) granted to Chief Scientific Officer
Exercise price
3.2000 per share
Conversion or exercise price of the stock option
Options after grant
52,832 options
Total derivative securities following the reported transaction
Option expiration date
2036-07-16
Expiration date of the granted stock options
First vesting date
July 16, 2027
50% of the options vest on the first anniversary of grant
Second vesting date
July 16, 2028
Remaining 50% of the options vest on the second anniversary of grant
Key Terms
Stock Option (Right to Buy), exercise price, vests and becomes exercisable, derivative securities
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 3.2000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests and becomes exercisable financial
"The stock option vests and becomes exercisable as to 50% of the options"
derivative securities financial
"reported as a derivative transaction in stock options"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Elicio Therapeutics (ELTX) report for Peter DeMuth?
Elicio Therapeutics reported that Chief Scientific Officer Peter DeMuth received a grant of 52,832 stock options. These options relate to common stock and were reported as an acquisition of derivative securities for compensation.
How many stock options did the ELTX Chief Scientific Officer receive and at what exercise price?
Chief Scientific Officer Peter DeMuth received 52,832 stock options with an exercise price of 3.2000 per share. Each option is a right to buy one share of Elicio Therapeutics common stock at that price.
What is the vesting schedule of the 52,832 ELTX stock options granted to Peter DeMuth?
The 52,832 stock options vest and become exercisable 50% on July 16, 2027 and the remaining 50% on July 16, 2028. Vesting is conditioned on Peter DeMuth’s continued service with Elicio Therapeutics through each vesting date.
When do the new stock options granted to ELTX’s Chief Scientific Officer expire?
The stock options granted to Chief Scientific Officer Peter DeMuth expire on 2036-07-16. After that expiration date, any unexercised options will no longer be exercisable for shares of Elicio Therapeutics common stock.
How many Elicio Therapeutics (ELTX) options does Peter DeMuth hold after this transaction?
Following this reported grant, Peter DeMuth holds 52,832 stock options in total as derivative securities. This figure reflects his holdings immediately after the grant reported in the insider transaction data.
Was the ELTX option grant to Peter DeMuth made under a Rule 10b5-1 trading plan?
The data indicate the Rule 10b5-1 checkbox is not marked, so this option grant was not reported as being made under a Rule 10b5-1 trading plan. It is reported simply as a grant or award acquisition.